Category: Peptide Q&A
-
What is the current status of MOTS-c in clinical development—phase I, II, or beyond—and what are the primary endpoints?
What is the current status of MOTS-c in clinical development—phase I, II, or beyond—and what are the primary endpoints?
-
How does MOTS-c compare to other mitochondrial peptides like SHLP2 or humanin in longevity and metabolic regulation?
How does MOTS-c compare to other mitochondrial peptides like SHLP2 or humanin in longevity and metabolic regulation?
-
Are there any recommended cycling protocols for MOTS-c use to prevent tolerance or downregulation?
Are there any recommended cycling protocols for MOTS-c use to prevent tolerance or downregulation?
-
MOTS-c: Dosing, Forms & Administration
MOTS-c — Dosing, Forms & Administration: evidence-based guide.
-
Does MOTS-c activate the Nrf2 antioxidant pathway, and what is its role in reducing oxidative damage?
Does MOTS-c activate the Nrf2 antioxidant pathway, and what is its role in reducing oxidative damage?
-
MOTS-c: Safety, Side Effects & Regulation
MOTS-c — Safety, Side Effects & Regulation: evidence-based guide.
-
What is the role of MOTS-c in modulating autophagy in aging or stressed cells?
What is the role of MOTS-c in modulating autophagy in aging or stressed cells?